Clinicians should personalize goals for glycemic control in patients with type 2 diabetes (T2D), according to new guidance released by The American College of Physicians (ACP). The guidance statement was developed to guide clinicians in selecting hemoglobin A_1c targets with pharmacologic therapy for nonpregnant adults with type 2 diabetes (T2D). Guidance statements include:

• Clinicians should personalize goals for glycemic control in patients with T2D on the basis of a discussion of benefits and harms of pharmacotherapy, patients' preferences, patients' general health and life expectancy, treatment burden, and costs of care.
• Clinicians should aim to achieve an HbA_1c level between 7% and 8% in most patients with T2D.
• Clinicians should consider deintensifying pharmacologic therapy in patients with T2D who achieve HbA_1c levels <6.5%.
• Clinicians should treat patients with T2D to minimize symptoms related to hyperglycemia and avoid targeting an HbA_1c level in patients with a life expectancy <10 years due to advanced age (≥80 years), residence in a nursing home, or chronic conditions (such as dementia, cancer, end-stage kidney disease, or severe chronic obstructive pulmonary disease or congestive heart failure) because the harms outweigh the benefits in this population.